Lanxess to Upgrade Saltigo Facilities

Lanxess will invest $52 million (Euro 40 million) to convert existing Saltigo sites in Leverkusen and Dormagen to the production of active pharmaceutical ingredients and intermediates. The company will also build a new multi-purpose plant. The investment is designed to improve Saltigo's profitability. Lanxess is also considering a new flextime system and asking employees to work longer hours without a raise in pay.

Back to News